BIOVICA International AB

BIOVICA International AB is a Swedish biotech company specializing in blood-based cancer diagnostics and treatment monitoring. Their flagship product is DiviTum® TKa, a blood test designed to monitor disease progression in solid tumors by measuring circulating tumor cell proliferation markers. The test is positioned for oncology applications, particularly in breast cancer management, to assess treatment efficacy and predict patient response to therapies such as CDK4/6 inhibitors and endocrine therapies. The company has conducted extensive clinical validation with over 4,500 patients enrolled in studies and maintains 28 peer-reviewed publications. DiviTum® TKa serves pharmaceutical companies, oncologists, and cancer patients by providing early indicators of treatment response—potentially within the first weeks of therapy—enabling more informed treatment decisions and disease monitoring. The company engages with major pharmaceutical partners across 32 pharma projects. Clinical evidence comes from leading oncology centers including University of Michigan Rogel Cancer Center and Washington University School of Medicine. The test represents a liquid biopsy approach for precision oncology decision-making.